Core Technology and Mechanism of Action

Mesoblast's foundational work is built on the unique properties of its mesenchymal lineage cells. These cells are isolated from the bone marrow of healthy adult donors and are capable of large-scale expansion in a laboratory setting, which is critical for their commercial viability as an allogeneic product. This "off-the-shelf" nature means the cellular medicine is cryopreserved and readily available, eliminating the need for patient-specific cell harvesting or donor-patient matching, and can be administered without the need for recipient immune suppression.

The primary function of these cells is not to simply replace damaged tissue but to act as a therapeutic signaling center. When administered intravenously or directly into the affected tissue, the cells migrate to sites of inflammation and tissue damage. Their key mechanisms of action involve:

• Immunomodulation: Regulating and suppressing the overactive immune response that causes damage in inflammatory diseases, such as acute graft versus host disease (aGVHD).
• Anti-inflammation: Releasing a diverse range of anti-inflammatory and anti-apoptotic molecules that dampen the inflammatory cascade.
• Tissue Repair and Regeneration: Stimulating the production of factors that encourage tissue repair, angiogenesis (new blood vessel formation), and reduce fibrosis (scarring).

Products and Services

Mesoblast's portfolio is characterized by its late-stage clinical candidates, all derived from its proprietary mesenchymal cell platform.

Marketed Product (Licensed)

• TEMCELL (remestemcel-L)
  • Indication: Treatment of acute graft versus host disease (aGVHD) in children and adults.
  • Status: Fully approved and marketed in Japan through its licensee, JCR Pharmaceuticals Co., Ltd. TEMCELL holds the distinction of being the first allogeneic cell therapy to achieve full regulatory approval in Japan.

Lead Product Candidates in Clinical Development

1. Remestemcel-L (Branded as Ryoncil in the US)

Remestemcel-L is an intravenous infusion of allogeneic mesenchymal stem cells (MSCs) primarily targeting severe inflammatory and immunologic conditions.

• Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
  • Focus: A life-threatening complication that can occur after an allogeneic bone marrow or hematopoietic stem cell transplant.
  • Development Stage: The candidate is the subject of an ongoing regulatory pathway in the United States, particularly for pediatric SR-aGVHD, where there are limited approved treatment options. Clinical data suggests remestemcel-L may significantly improve overall survival rates in this high-risk population.
• Acute Respiratory Distress Syndrome (ARDS)
  • Focus: Targeting the severe lung inflammation and failure characteristic of moderate to severe ARDS, including that associated with certain viral infections.
  • Development Stage: Mesoblast has pursued clinical trials to evaluate the efficacy of remestemcel-L in reducing mortality and improving outcomes in patients with ARDS.

2. Rexlemestrocel-L (MPC-150-IM/MPC-06-ID)

Rexlemestrocel-L is an allogeneic Mesenchymal Precursor Cell (MPC) candidate that is being developed for cardiovascular and musculoskeletal indications.

• Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
  • Focus: Administered via intramyocardial injection to patients with advanced chronic heart failure.
  • Development Stage (Branded as Revascor): Phase 3 clinical data indicated the greatest treatment benefit was observed in high-risk HFrEF patients with systemic inflammation (elevated baseline hs-CRP levels) and/or myocardial ischemia/diabetes, showing a reduction in Major Adverse Cardiovascular Events (MACE), specifically cardiovascular mortality or non-fatal heart attack or stroke.
• Chronic Discogenic Low Back Pain (CLBP)
  • Focus: A single injection directly into the degenerated intervertebral disc.
  • Development Stage (Branded as MPC-06-ID): Phase 3 clinical trials are underway to assess its efficacy in reducing pain and improving function in patients with chronic low back pain due to degenerative disc disease. The proposed mechanism involves the MPCs modulating inflammation and stimulating tissue-repair mechanisms within the damaged disc.

Strategic Operations and Commercialization

Mesoblast's business model is centered on leveraging strategic partnerships to commercialize its cellular medicines in major global markets. The company generates revenue through licensing fees, milestone payments from partners (like JCR Pharmaceuticals), and product sales. By focusing on conditions with high unmet medical need and utilizing its scalable, allogeneic technology, Mesoblast aims to establish its position as a key player in the commercialization of regenerative medicine globally.